Clindamycin Phosphate CAS 24729-96-2 with Antibiotic Drugs Lincomines

Melting point 114 °C
Boiling point 159°C
density 1.41±0.1 g/cm3(Predicted)
refractive index 122 ° (C=1, H2O)
storage temp. Sealed in dry,2-8°C
solubility DMSO: soluble224mg/mL at 25°C
form solid

Product Name: Clindamycin phosphate
Synonyms: (2s-trans)-;2-(dihydrogenphosphate;U-28508E;Clindamycin phosphate BP98,USP25,EP97;Clindaymcin Palmitate hydrochloride USP23;L-threo-.alpha.-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-(2S,4R)-1-methyl-4-propyl-2-pyrrolidinylcarbonylamino-1-thio-, 2-(dihydrogen phosphate);CLINDAMYCINPHOSPHATE,CRYSTAL,USP;CLINDAMYCIN PHOSPHATE/ 7-(S)-CHLORO-7-DEOXY-LINCOMYCIN-2-ORGANIC PHOSPHATE
CAS: 24729-96-2
MF: C18H34ClN2O8PS
MW: 504.96
EINECS: 246-433-0

Clindamycin phosphate is used topically alone or in conjunction with benzoyl peroxide in the treatment of inflammatory acne vulgaris. In weighing the potential benefits of topical clindamycin therapy, the possibility of serious adverse GI effects associated with the drug should be considered. Therapy of acne vulgaris must be individualized and frequently modified depending on the types of acne lesions which predominate and the response to therapy. Topical anti-infectives, including clindamycin, generally are effective in the treatment of mild to moderate inflammatory acne. However, use of topical anti-infectives as monotherapy may lead to bacterial resistance; this resistance is associated with decreased clinical efficacy.Topical clindamycin is particularly useful when used with benzoyl peroxide or topical retinoids. Results of clinical studies indicate that combination therapy results in a reduction in total lesion counts of 50-70%.